BioTelemetry (BEAT) Tops Q2 EPS by 2c; Raises Outlook

BioTelemetry (NASDAQ: BEAT) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $58.1 million versus the consensus estimate of $58.39 million.

Increases full year 2017 revenue guidance to $285 million to $290 million, with expected adjusted EBITDA of approximately 23% of revenue.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight